Linking Registry and Administrative Data in Ontario to Study Characteristics and Outcomes of Patients with NMOSD

Summary

Client: IQVIA Solutions Canada Inc.

Project ID: P2024-227/ 2026 0980 013 000

Research Question/Objectives: Neuromyelitis Optica Spectrum Disorder (NMOSD), also known as Neuromyelitis Optica or Devic disease, is a rare autoimmune condition of the central nervous system characterized by inflammation, demyelination, and damage to the optic nerves, spinal cord, and brain. It is often misdiagnosed as multiple sclerosis (MS) but requires distinct treatment and management.

Given the high prevalence of anti-aquaporin-4 (anti-AQP4) and myelin oligodendrocyte glycoprotein (MOG) antibodies in NMOSD patients, and the significant impact of relapses on patient health and healthcare costs, there is a critical need for real-world evidence on NMOSD in Ontario to inform better management and treatment strategies.

Objectives: 

The primary objectives of the study are to:

1. Describe the demographic, socioeconomic, and clinical characteristics of NMOSD patients and matched controls in Ontario, Canada.
2. Describe all-cause healthcare resource utilization (HCRU) and direct costs of NMOSD patients and matched controls in Ontario, Canada.
3. Describe clinical outcomes of NMOSD patients in Ontario, Canada.

Additionally, the study will examine the following exploratory objective(s):

1. Explore variations in the primary objectives across course of disease and NMOSD sub-populations in Ontario, Canada.
2. Explore treatment patterns of NMOSD patients and NMOSD sub-populations in Ontario, Canada.
3. Describe the demographic, socioeconomic, and clinical characteristics of matched multiple sclerosis (MS) patients in Ontario, Canada.
4. Describe all-cause healthcare resource utilization (HCRU) and direct costs of matched MS patients in Ontario, Canada.

Status: In progress